The former leader of China’s Centre for Disease Control implies that an official investigation was carried out by Beijing into the Wuhan lab.
Poolbeg Pharma PLC – Board Appointment
 Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
hVIVO PLC Annual Report and Notice of AGM
hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced
GSK’s shares have opened higher after sales and profits for the first quarter exceeded expectations.
GSK’s shares rose at the opening of trading after the company reported that its Q1 revenue and profits had exceeded expectations, driven by the success of its Shingrix shingles vaccine.
hVIVO PLC FDA Breakthrough and Fast Track for US biotech
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).
hVIVO PLC (AIM:HVO) Final results
Transformational year with record EBITDA underlining strong operational delivery
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s
hVIVO PLC (AIM:HVO) Positive results from flu human challenge study
Positive results from influenza human challenge study conducted by hVIVO
Poolbeg Pharma PLC (AIM:POLB) Results for the year ended 31 December 2022
Significant milestones reached, well capitalised and positioned for future growth
hVIVO PLC (AIM:HVO) World Vaccine Congress Presentation
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using